KR102603013B1 - 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법 - Google Patents

부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법 Download PDF

Info

Publication number
KR102603013B1
KR102603013B1 KR1020227013910A KR20227013910A KR102603013B1 KR 102603013 B1 KR102603013 B1 KR 102603013B1 KR 1020227013910 A KR1020227013910 A KR 1020227013910A KR 20227013910 A KR20227013910 A KR 20227013910A KR 102603013 B1 KR102603013 B1 KR 102603013B1
Authority
KR
South Korea
Prior art keywords
dextromethorphan
bupropion
day
administered
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227013910A
Other languages
English (en)
Korean (ko)
Other versions
KR20220054909A (ko
Inventor
헤리엇 타부토
Original Assignee
안테씨프 바이오벤쳐스 투 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안테씨프 바이오벤쳐스 투 엘엘씨 filed Critical 안테씨프 바이오벤쳐스 투 엘엘씨
Priority to KR1020237034772A priority Critical patent/KR20230148385A/ko
Publication of KR20220054909A publication Critical patent/KR20220054909A/ko
Application granted granted Critical
Publication of KR102603013B1 publication Critical patent/KR102603013B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227013910A 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법 Active KR102603013B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237034772A KR20230148385A (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361900354P 2013-11-05 2013-11-05
US61/900,354 2013-11-05
KR1020217016618A KR20210068157A (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
PCT/US2014/064184 WO2015069809A1 (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217016618A Division KR20210068157A (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237034772A Division KR20230148385A (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20220054909A KR20220054909A (ko) 2022-05-03
KR102603013B1 true KR102603013B1 (ko) 2023-11-15

Family

ID=53042051

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227013910A Active KR102603013B1 (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
KR1020217016618A Ceased KR20210068157A (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
KR1020237034772A Pending KR20230148385A (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
KR1020167013970A Active KR102264179B1 (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020217016618A Ceased KR20210068157A (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
KR1020237034772A Pending KR20230148385A (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
KR1020167013970A Active KR102264179B1 (ko) 2013-11-05 2014-11-05 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

Country Status (12)

Country Link
EP (3) EP3981404A1 (https=)
JP (5) JP6605485B2 (https=)
KR (4) KR102603013B1 (https=)
CN (7) CN110327338A (https=)
AU (7) AU2014346807B2 (https=)
CA (4) CA3175703C (https=)
IL (3) IL298972A (https=)
MX (3) MX388666B (https=)
MY (1) MY179696A (https=)
NZ (1) NZ758428A (https=)
SG (4) SG11201603391XA (https=)
WO (1) WO2015069809A1 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
CN110327338A (zh) * 2013-11-05 2019-10-15 安泰赛普生物风投二代有限责任公司 包含安非他酮或相关化合物和右美沙芬的组合物和方法
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
CN117427077A (zh) * 2014-09-14 2024-01-23 阿瓦尼尔制药股份有限公司 用于治疗痴呆中的激越行为的包含右美沙芬化合物和奎尼丁的药物组合物
PT3220909T (pt) * 2014-11-21 2020-12-07 Antecip Bioventures Ii Llc Bupropiona para modular os níveis plasmáticos de fármaco de dextrometorfano
WO2017165845A1 (en) * 2016-03-24 2017-09-28 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
TWI795446B (zh) 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
US20230225995A1 (en) * 2019-01-07 2023-07-20 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
KR20210110654A (ko) * 2019-01-07 2021-09-08 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 치료를 위한 덱스트로메토르판과 부프로피온의 조합
JP7637150B2 (ja) * 2020-03-30 2025-02-27 アンテシップ バイオベンチャーズ トゥー エルエルシー 神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
CN117100750A (zh) * 2020-07-20 2023-11-24 深圳信立泰药业股份有限公司 一种药物组合物及其应用
KR20230113787A (ko) 2020-12-01 2023-08-01 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 환자의 자살 위험 감소를 위한 부프로피온 및덱스트로메토르판
AU2022207514A1 (en) * 2021-01-18 2023-07-27 Antecip Bioventures Ii Llc Combination of an antidepressant and dextromethorphan for neuropsychiatric conditions
CN112999350A (zh) * 2021-02-23 2021-06-22 北京斯利安药业有限公司 一种药物组合物、复方制剂及其制备方法与应用
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
CN118785900A (zh) * 2022-06-30 2024-10-15 艾克萨姆治疗公司 包含安非他酮和半胱氨酸的药物组合物
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006194A1 (en) * 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
KR102264179B1 (ko) * 2013-11-05 2021-06-11 안테씨프 바이오벤쳐스 투 엘엘씨 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
CA2289190A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
CA2641392A1 (en) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006194A1 (en) * 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
KR102264179B1 (ko) * 2013-11-05 2021-06-11 안테씨프 바이오벤쳐스 투 엘엘씨 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Clinical Psychopharmacology, 25(3), pp.226-229(2005)*

Also Published As

Publication number Publication date
CA2929415C (en) 2023-01-03
KR20160070158A (ko) 2016-06-17
MX388666B (es) 2025-03-20
AU2021202497A1 (en) 2021-05-27
JP2023129646A (ja) 2023-09-14
MX2016005867A (es) 2016-07-15
CN113750099A (zh) 2021-12-07
SG11201603391XA (en) 2016-05-30
IL283760B2 (en) 2023-05-01
CA3256217A1 (en) 2025-10-30
JP2020023543A (ja) 2020-02-13
SG10201911808QA (en) 2020-01-30
AU2018203638A1 (en) 2018-06-14
AU2019275593B2 (en) 2021-01-28
CA3175703A1 (en) 2015-05-14
IL298972A (en) 2023-02-01
MX2020004075A (es) 2021-12-10
AU2018203638C1 (en) 2019-10-24
CA3154845C (en) 2023-02-28
KR102264179B1 (ko) 2021-06-11
CN113750098A (zh) 2021-12-07
JP2025175199A (ja) 2025-11-28
JP2021169527A (ja) 2021-10-28
KR20220054909A (ko) 2022-05-03
SG10201810888XA (en) 2019-01-30
IL245504A0 (en) 2016-06-30
JP6605485B2 (ja) 2019-11-13
CN110279682A (zh) 2019-09-27
AU2021202497B2 (en) 2023-03-02
NZ758431A (en) 2021-07-30
CA3175703C (en) 2025-08-05
AU2025230795A1 (en) 2025-10-02
EP3981403A1 (en) 2022-04-13
CA3154845A1 (en) 2015-05-14
NZ758428A (en) 2021-07-30
AU2023203438B2 (en) 2025-06-26
MX373330B (es) 2020-05-04
SG10201911816XA (en) 2020-01-30
MX2021015234A (es) 2022-05-26
AU2014346807A1 (en) 2016-05-19
KR20230148385A (ko) 2023-10-24
WO2015069809A1 (en) 2015-05-14
NZ758425A (en) 2021-07-30
CN106163522A (zh) 2016-11-23
KR20210068157A (ko) 2021-06-08
IL283760B1 (en) 2023-01-01
CA2929415A1 (en) 2015-05-14
NZ758432A (en) 2021-07-30
NZ719892A (en) 2021-07-30
EP3065742A4 (en) 2017-04-05
JP2016535786A (ja) 2016-11-17
AU2014346807B2 (en) 2018-03-22
EP3981404A1 (en) 2022-04-13
AU2019236614C1 (en) 2021-10-14
AU2023203438A1 (en) 2023-07-06
CN113797205A (zh) 2021-12-17
CN110327338A (zh) 2019-10-15
CN110251517A (zh) 2019-09-20
AU2019236614B2 (en) 2021-07-15
JP6927601B2 (ja) 2021-09-01
MY179696A (en) 2020-11-11
EP3065742A1 (en) 2016-09-14
AU2019275593A1 (en) 2020-01-02
AU2019236614A1 (en) 2019-10-17
IL245504B (en) 2021-06-30
AU2018203638B2 (en) 2019-07-18
IL283760A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
KR102603013B1 (ko) 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
KR102640586B1 (ko) 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
US9457025B2 (en) Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US9205083B2 (en) Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
HK40063443A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40064612A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40068779A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40063444A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40069223A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40015601A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40014888A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40014464A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601